Literature DB >> 26456931

Expression of activation-induced cytidine deaminase enhances the clearance of pneumococcal pneumonia: evidence of a subpopulation of protective anti-pneumococcal B1a cells.

Natsuo Yamamoto1,2, Steven M Kerfoot1, Andrew T Hutchinson1, Charles S Dela Cruz1, Naomi Nakazawa2, Marian Szczepanik1,3, Monika Majewska-Szczepanik1,3, Katarzyna Nazimek1,4, Noboru Ohana2, Krzysztof Bryniarski1,4, Tsutomu Mori2, Masamichi Muramatsu5, Keiji Kanemitsu2, Philip W Askenase1.   

Abstract

We describe a protective early acquired immune response to pneumococcal pneumonia that is mediated by a subset of B1a cells. Mice deficient in B1 cells (xid), or activation-induced cytidine deaminase (AID(-/-) ), or invariant natural killer T (iNKT) cells (Jα18(-/-) ), or interleukin-13 (IL-13(-/-) ) had impaired early clearance of pneumococci in the lung, compared with wild-type mice. In contrast, AID(-/-) mice adoptively transferred with AID(+/+) B1a cells, significantly cleared bacteria from the lungs as early as 3 days post infection. We show that this early bacterial clearance corresponds to an allergic contact sensitivity-like cutaneous response, probably due to a subpopulation of initiating B1a cells. In the pneumonia model, these B1a cells were found to secrete higher affinity antigen-specific IgM. In addition, as in contact sensitivity, iNKT cells were required for the anti-pneumococcal B1a cell initiating response, probably through early production of IL-13, given that IL-13(-/-) mice also failed to clear infection. Our study is the first to demonstrate the importance of AID in generating an appropriate B1a cell response to pathogenic bacteria. Given the antibody affinity and pneumonia resistance data, natural IgM produced by conventional B1a cells are not responsible for pneumonia clearance compared with the AID-dependent subset.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  B1a cells; IgM antibody; activation-induced cytidine deaminase; interleukin-13; invariant natural killer T cells; pneumococcal pneumonia

Mesh:

Substances:

Year:  2016        PMID: 26456931      PMCID: PMC4693878          DOI: 10.1111/imm.12544

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  41 in total

1.  Control of early viral and bacterial distribution and disease by natural antibodies.

Authors:  A F Ochsenbein; T Fehr; C Lutz; M Suter; F Brombacher; H Hengartner; R M Zinkernagel
Journal:  Science       Date:  1999-12-10       Impact factor: 47.728

Review 2.  B-1 B cell IgM antibody initiates T cell elicitation of contact sensitivity.

Authors:  P W Askenase; R F Tsuji
Journal:  Curr Top Microbiol Immunol       Date:  2000       Impact factor: 4.291

3.  B-1 B cells mediate required early T cell recruitment to elicit protein-induced delayed-type hypersensitivity.

Authors:  Marian Szczepanik; Moe Akahira-Azuma; Krzysztof Bryniarski; Ryohei F Tsuji; Ivana Kawikova; Wlodzimierz Ptak; Claudia Kiener; Regis A Campos; Philip W Askenase
Journal:  J Immunol       Date:  2003-12-01       Impact factor: 5.422

4.  An hour after immunization peritoneal B-1 cells are activated to migrate to lymphoid organs where within 1 day they produce IgM antibodies that initiate elicitation of contact sensitivity.

Authors:  Atsuko Itakura; Marian Szczepanik; Regis A Campos; Vipin Paliwal; Monika Majewska; Hiroshi Matsuda; Kiyoshi Takatsu; Philip W Askenase
Journal:  J Immunol       Date:  2005-12-01       Impact factor: 5.422

5.  Early local generation of C5a initiates the elicitation of contact sensitivity by leading to early T cell recruitment.

Authors:  R F Tsuji; I Kawikova; R Ramabhadran; M Akahira-Azuma; D Taub; T E Hugli; C Gerard; P W Askenase
Journal:  J Immunol       Date:  2000-08-01       Impact factor: 5.422

Review 6.  Somatic hypermutation of immunoglobulin genes: merging mechanisms for genetic diversity.

Authors:  F Nina Papavasiliou; David G Schatz
Journal:  Cell       Date:  2002-04       Impact factor: 41.582

Review 7.  Origins and functions of B-1 cells with notes on the role of CD5.

Authors:  Robert Berland; Henry H Wortis
Journal:  Annu Rev Immunol       Date:  2001-10-04       Impact factor: 28.527

8.  Analysis of class switch recombination and somatic hypermutation in patients affected with autosomal dominant hyper-IgM syndrome type 2.

Authors:  Kohsuke Imai; Yi Zhu; Patrick Revy; Tomohiro Morio; Shuki Mizutani; Alain Fischer; Shigeaki Nonoyama; Anne Durandy
Journal:  Clin Immunol       Date:  2005-06       Impact factor: 3.969

9.  B cell clones that sustain long-term plasmablast growth in T-independent extrafollicular antibody responses.

Authors:  Mei-Chi Hsu; Kai-Michael Toellner; Carola G Vinuesa; Ian C M Maclennan
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-03       Impact factor: 11.205

10.  AID induces intraclonal diversity and genomic damage in CD86(+) chronic lymphocytic leukemia cells.

Authors:  Michael Huemer; Stefan Rebhandl; Nadja Zaborsky; Franz J Gassner; Stefan Hainzl; Lukas Weiss; Daniel Hebenstreit; Richard Greil; Roland Geisberger
Journal:  Eur J Immunol       Date:  2014-10-18       Impact factor: 5.532

View more
  11 in total

Review 1.  Functions of Exosomes and Microbial Extracellular Vesicles in Allergy and Contact and Delayed-Type Hypersensitivity.

Authors:  Katarzyna Nazimek; Krzysztof Bryniarski; Philip W Askenase
Journal:  Int Arch Allergy Immunol       Date:  2016-11-08       Impact factor: 2.749

2.  Corrigendum.

Authors: 
Journal:  Immunology       Date:  2017-02       Impact factor: 7.397

3.  Vaccination with a live attenuated Acinetobacter baumannii deficient in thioredoxin provides protection against systemic Acinetobacter infection.

Authors:  Sarah Ainsworth; Patrick M Ketter; Jieh-Juen Yu; Rose C Grimm; Holly C May; Andrew P Cap; James P Chambers; M Neal Guentzel; Bernard P Arulanandam
Journal:  Vaccine       Date:  2017-05-15       Impact factor: 3.641

Review 4.  Integrative Physiology of Pneumonia.

Authors:  Lee J Quinton; Allan J Walkey; Joseph P Mizgerd
Journal:  Physiol Rev       Date:  2018-07-01       Impact factor: 37.312

5.  Effect of CARD9 Deficiency on Neutrophil-Mediated Host Defense against Pulmonary Infection with Streptococcus pneumoniae.

Authors:  Shigenari Ishizuka; Rin Yokoyama; Ko Sato; Ryuhei Shiroma; Ayako Nakahira; Hideki Yamamoto; Kazuki Takano; Takafumi Kagesawa; Tomomitsu Miyasaka; Jun Kasamatsu; Emi Kanno; Hiromasa Tanno; Keiko Ishii; Kazuyoshi Kawakami
Journal:  Infect Immun       Date:  2020-12-15       Impact factor: 3.441

Review 6.  A subset of AID-dependent B-1a cells initiates hypersensitivity and pneumococcal pneumonia resistance.

Authors:  Phillip W Askenase; Krzysztof Bryniarski; Vipin Paliwal; Frank Redegeld; Thomas Groot Kormelink; Steven Kerfoot; Andrew T Hutchinson; Henk van Loveren; Regis Campos; Atsuko Itakura; Monika Majewska-Szczepanik; Natsuo Yamamoto; Katarzyn Nazimek; Marian Szczepanik; Wold Ptak
Journal:  Ann N Y Acad Sci       Date:  2015-12       Impact factor: 5.691

Review 7.  Invariant natural killer T cells balance B cell immunity.

Authors:  Elizabeth A Leadbetter; Mikael C I Karlsson
Journal:  Immunol Rev       Date:  2021-01-12       Impact factor: 12.988

Review 8.  Expansion and Sub-Classification of T Cell-Dependent Antibody Responses to Encompass the Role of Innate-Like T Cells in Antibody Responses.

Authors:  Chanho Park; Tae Jin Kim
Journal:  Immune Netw       Date:  2018-10-23       Impact factor: 6.303

9.  Antibody Light Chains Dictate the Specificity of Contact Hypersensitivity Effector Cell Suppression Mediated by Exosomes.

Authors:  Katarzyna Nazimek; Philip W Askenase; Krzysztof Bryniarski
Journal:  Int J Mol Sci       Date:  2018-09-07       Impact factor: 5.923

10.  Orally Administered Exosomes Suppress Mouse Delayed-Type Hypersensitivity by Delivering miRNA-150 to Antigen-Primed Macrophage APC Targeted by Exosome-Surface Anti-Peptide Antibody Light Chains.

Authors:  Katarzyna Nazimek; Krzysztof Bryniarski; Wlodzimierz Ptak; Tom Groot Kormelink; Philip W Askenase
Journal:  Int J Mol Sci       Date:  2020-08-02       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.